Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
March 25, 2021 16:05 ET
|
Eyenovia, Inc.
Announces MydCombi expected PDUFA date of October 28, 2021 Completes patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; topline data on track for Q2 ...
Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25
March 18, 2021 08:00 ET
|
Eyenovia, Inc.
NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose...
Eyenovia to Participate in the 33rd Annual Roth Conference
March 10, 2021 08:00 ET
|
Eyenovia, Inc.
NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary...
Eyenovia to Host Key Opinion Leader Webinar on Presbyopia
February 16, 2021 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event
January 06, 2021 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Reports Third Quarter 2020 Financial Results
November 10, 2020 16:06 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
November 05, 2020 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million
October 13, 2020 07:00 ET
|
Eyenovia, Inc.
Company reaffirms near term milestones for the Mydcombi™ (MicroStat) NDA and the MicroLine presbyopia program Phase III results Call scheduled for today, Tuesday, October 13 at 4:30pm ET ...
Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference
September 09, 2020 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering
August 24, 2020 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...